(PDF) Evaluation of the Effect of Sodium

Evaluation of the Effect of Sodium–glucose Co‐transporter 2 Inhibition With Empagliflozin on Morbidity and Mortality of Patients With Chronic Heart Failure and a Reduced Ejection Fraction: Rationale for and Design of the EMPEROR‐Reduced Trial

European Journal of Heart Failure - United States

doi 10.1002/ejhf.1536

Full Text

Open PDF

Abstract

Available in full text

Date

July 16, 2019

Authors

Milton Packer

Javed Butler

Gerasimos S. Filippatos

Hans Pieter Brunner La Rocca

Piotr Ponikowski

Jose Ramon Gonzalez Juanatey

Publisher

Wiley

Amanote Research

Evaluation of the Effect of Sodium–glucose Co‐transporter 2 Inhibition With Empagliflozin on Morbidity and Mortality of Patients With Chronic Heart Failure and a Reduced Ejection Fraction: Rationale for and Design of the EMPEROR‐Reduced Trial

European Journal of Heart Failure - United States

doi 10.1002/ejhf.1536

Full Text

Abstract

Categories

Date

Authors

Publisher

Related search

Evaluation of the Effects of Sodium–glucose Co‐transporter 2 Inhibition With Empagliflozin on Morbidity and Mortality in Patients With Chronic Heart Failure and a Preserved Ejection Fraction: Rationale for and Design of the EMPEROR‐Preserved Trial

Empagliflozin in Heart Failure Patients With Reduced Ejection Fraction: A Randomized Clinical Trial (Empire HF)

Rationale and Design of the EMPERIAL-Preserved and EMPERIAL-Reduced Trials of Empagliflozin in Patients With Chronic Heart Failure

The Outcomes of Chronic Kidney Disease and Heart Failure With Reduced Ejection Fraction

Hydralazine/Isosorbide Dinitrate, Blood Pressure and Mortality in Patients With Heart Failure With Reduced Ejection Fraction

Evaluation of the Effects of Various Treatment Modalities on Angiogenesis in Heart Failure With Reduced Ejection Fraction and Heart Failure Mid-Range Ejection Fraction Patients Without Chronic Kidney Disease via Angiostatin

Cardiovascular Volume Reserve in Patients With Heart Failure and Reduced Ejection Fraction

Heart Failure; Co-Relation of QRS Duration With Atrial Fibrillation in Patients With Reduced Ejection Fraction

Prognosis of Heart Failure With Stable Mid-Range Ejection Fraction in Comparison to Heart Failure With Stable Reduced Ejection Fraction and Heart Failure With Stable Preserved Ejection Fraction